ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Sparing the Nephron in Liver Transplant Recipients with Antithymocyte Bridging: A Four Year Experience

N. Wilson, H. Kuzaro, N. Parrish, S. A. Shah, N. Anwar, R. R. Alloway, S. Tremblay, T. E. Kaiser

U Cincinnati, Cincinnati, OH

Meeting: 2020 American Transplant Congress

Abstract number: C-137

Keywords: Glomerular filtration rate (GFR), Immunosuppression, Liver transplantation, Renal dysfunction

Session Information

Session Name: Poster Session C: Liver - Kidney Issues in Liver Transplantation

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Renal function decline after liver transplant (LT) remains a significant issue. Using antithymocyte globulin (rATG) to delay tacrolimus (TAC) initiation may impact renal deterioration; however long term impact is unknown. This study evaluated 4-year outcomes following rATG bridge with delayed CNI for renal sparing post-LT.

*Methods: This retrospective, single center, cohort study (7/2014-5/2018) evaluated patients (pts) with serum creatinine (SCr) >2 mg/dL prior to LT (PRE group) or who required CRRT/had a SCr >2 mg/dL within 48 hours of LT (POST group) that received rATG 1.5mg/kg/dose according to CD3 suppression (<25 cells /uL) for 7 days with delayed TAC initiation. TAC trough targets until day 90 were 6-8 ng/mL, then 3-6 ng/mL. Prior LT, multiorgan transplant, graft loss by 1 year (yr), or enrollment in another study were excluded. Estimated glomerular filtration rates (eGFR) and chronic kidney disease (CKD) category was measured on post-operative day 1, 2, 7, 14, twice monthly to month 12, and twice yearly to yr 4. Due to improved accuracy before and after LT, eGFR was assessed via the Glomerular Filtration Rate Assessment in Liver Disease Model (GRAIL) calculation. Other outcomes include: rATG bridge protocol adherence, patient/graft survival, biopsy-proven acute rejection (BPAR), infection (received treatment for cytomegalovirus, bacterial or fungal infection), and malignancy (any diagnosis of cancer post-LT).

*Results: 65 LT pts (27 PRE and 38 POST) were included; 106 excluded. Demographics were similar between PRE and POST groups with the exception of MELD at match (median of 35 PRE and 22 in POST groups). Outcomes summarized in Table 1. At 4 yrs post-LT, mean eGFR was 66 and 68 mL/min/1.73m2 for the PRE and POST respectively. CKD remained stable over time with majority in stage 2 (Figures 1 and 2). rATG was administered per protocol in 94%; rATG dosing was altered in 4 pts due to tolerability. 6 episodes of BPAR occurred in 5 pts (median 323 days post-LT); treated successfully with steroids and/or increased immunosuppression. Infection occurred in 45% within 1 yr (median 46 days post-LT). Malignancy occurred in 5 pts within 4 yrs (median 2.2 yrs post-LT). 3 died after 1 yr (median 3.2 yrs post-LT).

*Conclusions: Our data demonstrates that rATG is safe and effective post-LT to delay TAC. Renal function calculated via GRAIL not only recovered rapidly post-LT but did not decline and remained excellent at CKD stage 2 over the 4 yr study period. Next steps will be to compare these findings to the cohort of LT pts without renal dysfunction that did not receive rATG bridge protocol.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Wilson N, Kuzaro H, Parrish N, Shah SA, Anwar N, Alloway RR, Tremblay S, Kaiser TE. Sparing the Nephron in Liver Transplant Recipients with Antithymocyte Bridging: A Four Year Experience [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/sparing-the-nephron-in-liver-transplant-recipients-with-antithymocyte-bridging-a-four-year-experience/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences